Neil F. McFarlane is the President and CEO of Zevra Therapeutics, Inc., a role he stepped into in October 2023. He brings over 25 years of experience in the biopharmaceutical field, which includes high-level positions at companies like Adamas Pharmaceuticals...

Neil F. McFarlane is the President and CEO of Zevra Therapeutics, Inc., a role he stepped into in October 2023. He brings over 25 years of experience in the biopharmaceutical field, which includes high-level positions at companies like Adamas Pharmaceuticals and Retrophin, where he was responsible for significant operational oversight. McFarlane also has a military background, having served as an officer in the United States Army Reserves. He earned both a B.S. and an M.S. in Nursing from the University of Florida, a unique educational foundation for a leader in the biopharmaceutical space. In terms of compensation, he started with an annual salary of $700,000 and has an interesting bonus structure which reflects the company’s achievements in development and finance. His earlier role as a director of Collegium Pharmaceutical further highlights his extensive industry connections and insights. McFarlane's leadership style focuses on aligning executive interests with company goals, making him a strategic fit for driving Zevra's success in the competitive landscape of therapeutics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Zevra Therapeutics, Inc. CEOs

Z

Neil F. McFarlane

CEO of Zevra Therapeutics, Inc.

Education

B.S. and M.S. degrees in Nursing from the University of Florida

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of Zevra Therapeutics, Inc. for

1 year 7 months (Oct 2023 - Present)

Previous Experience

Chief Executive Officer of Adamas Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Neil F. McFarlane

Holdings

See how much did Neil F. McFarlane make over time.

As the CEO of Zevra Therapeutics, Neil F. McFarlane holds a significant position in the company's stock ownership. He was granted 600,000 stock options with an exercise price set at $4.75. These options will vest equally over four years, aligning...

As the CEO of Zevra Therapeutics, Neil F. McFarlane holds a significant position in the company's stock ownership. He was granted 600,000 stock options with an exercise price set at $4.75. These options will vest equally over four years, aligning his financial incentives with the company’s long-term success. Additionally, he has been awarded 200,000 restricted stock units, which will also vest in four equal parts starting one year after his appointment. This structure not only shows a strong commitment from him towards the company's goals but also ties his potential earnings to the performance of Zevra’s stock. Given the stock price at the time of his option grant, there is a noticeable upside potential for McFarlane based on Zevra’s future valuation. His significant stakes in the company add a layer of responsibility as he drives its growth.

No data yet.

Insider Trading

See recent insider trades of Neil F. McFarlane.

No insider trades found for this CEO.

Compensation History

See how much did Neil F. McFarlane make over time.

In 2023, Neil F. McFarlane's total compensation package amounted to $3.45 million. This includes his base salary of $700,000, a bonus of $200,000 tied to corporate performance goals, and substantial equity grants. Notably, $2.2 million of his compensation came from stock options and restricted stock units. Not only does this reflect the commitment from Zevra Therapeutics to attract top talent, but also indicates that McFarlane's earnings are significantly performance-driven. The bonuses are directly linked to milestones like drug development and regulatory achievements, which are crucial in the biopharmaceutical space. This structure demonstrates Zevra's strategic approach to executive compensation, ensuring alignment with shareholders’ interests and company objectives.

Year

2023

Total Compensation

$1.71M

Salary

$157.50K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate talented executives, aligning their interests with those of stockholders through performance-based incentives.

Bonus

$200.00K

Board Justification

The bonus is based on the achievement of specified corporate performance objectives, pro-rated for the partial year of employment.

Other

$40.74K

Board Justification

Includes 401(k) employer matching contributions, travel reimbursements, gross-up tax payments, and legal fee reimbursements related to his employment agreement.

Restricted Stock

$1.31M(200K RSU)

Board Justification

The RSUs granted to Mr. McFarlane vest in four equal annual installments, beginning on the first anniversary of his start date, subject to continuous service.

Performance Metrics

Performance metrics include the achievement of specified development, regulatory, and financial milestones.

Other Zevra Therapeutics, Inc. CEOs

Here are other CEOs of Zevra Therapeutics, Inc.

Christal M.M. Mickle

Founder and Ex-CEO of Zevra Therapeutics, Inc.

June 2023 - October 2023